Relationship between metabolic control and long-term complications of diabetes

Joslin's Diabetes Mellitus: Fourteenth Edition

Volumn , Issue , 2011, Pages 809-821

  Nathan, David M ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84970983718     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (115)

1. Cahill GF Jr, Etzwiler DD, Freinkel N. "Control" and diabetes [Editorial]. . Engl J Med 1976;294:1004-1005.
2. Siperstein MD, Foster DW, Knowles HC Jr, et al. Control of blood glucose and diabetic vascular disease [Editorial]. . Engl J Med 1977;296:1060-1063.
3. Ingelfinger FJ. Debates on diabetes. . Engl J Med 1977;296:1228-1230.
4. Siperstein MD. Diabetic microangiopathy and the control of blood glucose. . Engl J Med 1983;309:1577-1579.
5. Stern MP, Haffner SM. Prospective assessment of metabolic control in diabetes mellitus: the complications question. JAMA 1988;260:2896-2897.
6. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. . Engl J Med 1993;329:977-986.
7. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853.
8. Von Engelhardt D, et al, eds. Diabetes: its medical and cultural history. New York: Springer-Verlag, 1989.
9. Nettleship E. Chronic retinitis, with formation of blood-vessels in the vitreous in a patient with diabetes; one eye lost by results of chronic iritis, accompanied by the formation of large vessels in the iris. Trans Ophthalmol Soc UK 1888;8:159-161.
10. Ballantyne AJ, Loewenstein A. The pathology of diabetic retinopathy. Trans Ophthalmol UK 1943;63:95-115.
11. Kimmelstiel P, Wilson C. Intercapillary lesions in the glomeruli of the kidney. Am J Pathol 1936;12:83-97.
12. Palmberg P, Smith M, Waltman S, et al. The natural history of retinopathy in insulin-dependent juvenile-onset diabetes. Ophthalmology 1981;88:613-618.
13. Frank RN, Hoffman WH, Podgor MJ, et al. Retinopathy in juvenile-onset type I diabetes of short duration. Diabetes 1982;31:874-884.
14. Klein R, Klein BEK, Moss SE, et al. The Wisconsin epidemiologic study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol 1984;102:527-532.
15. Klein R, Klein BEK, Moss SE, et al. The Wisconsin epidemiologic study of diabetic retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 1984;102:520-526.
16. Nathan DM, Singer DE, Godine JE, et al. Retinopathy in older type II diabetics: association with glucose control. Diabetes 1986;35:797-801.
17. Ballard DJ, Melton LJ III, Dwyer MS, et al. Risk factors for diabetic retinopathy: a population-based study in Rochester, Minnesota. Diabetes Care 1986; 334-342.
18. Krolewski AS, Warram JH, Rand LI, et al. Risk of proliferative diabetic retinopathy in juvenile-onset type I diabetes: a-40 year follow-up study. Diabetes Care 1986;9:443-452.
19. White P. The future of the diabetic child. JAMA 1930;95:1160-1162.
20. Joslin EP. Insulin's twenty-fifth anniversary. Diabetes Abstracts 1945;5:37.
21. Wagener HP. Retinopathy in diabetes mellitus. Proc Am Diabetes Assoc 1943;5:201-216.
22. Dolger H. Clinical evaluation of vascular damage in diabetes mellitus. JAMA 1947;134:1289-1291.
23. Boyd JD, Jackson RL, Allen JH. Avoidance of degenerative lesions in diabetes mellitus. JAMA 1942;118:694-696.
24. Harris MI, Hadden WC, Knowler WC, et al. Prevalence of diabetes and impaired glucose tolerance and plasma glucose levels in U.S. population aged 20-74 yr. Diabetes 1987;36:523-524.
25. Nathan DM, Singer DE, Godine JE, et al. Non-insulin-dependent diabetes in older patients. Am J Med 1986;81:837-842.
26. Humphrey LL, Ballard DJ, Frohnert PP, et al. Chronic renal failure in noninsulin-dependent diabetes mellitus: a population based study in Rochester, Minnesota. Ann Intern Med 1989;111:788-796.
27. Cowie CC, Port FK, Wolfe RA, et al. Disparities in incidence of diabetic endstage renal disease according to race and type of diabetes. . Engl J Med 1989; 321:1074-1079.
28. Dwyer MS, Melton LJ III, Ballard DJ, et al. Incidence of diabetic retinopathy and blindness: a population based study in Rochester Minnesota. Diabetes Care 1985;8:316-322.
29. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20:1183-1197.
30. Engerman R, Bloodworth JMB Jr, Nelson S. Relationship of microvascular disease in diabetes to metabolic control. Diabetes 1977;26:760-769.
31. Engerman RL, Kern TS. Progression of incipient diabetic retinopathy during good glycemic control. Diabetes 1987;36:808-812.
32. Mauer SM, Steffes MW, Sutherland DER, et al. Studies of the rate of regression of the glomerular lesions in diabetic rats treated with pancreatic islet transplantation. Diabetes 1975;24:280-285.
33. Gray BN, Watkins E Jr. Prevention of vascular complications of diabetes by pancreatic islet transplantation. Arch Surg 1976;254-257.
34. Cohen AJ, McGill PD, Rossetti RG, et al. Glomerulopathy in spontaneously diabetic rat. Diabetes 1977;36:944-951.
35. Knowles HC Jr. The problem of the relation of the control of diabetes to the development of vascular disease. Trans Am Clin Climatol Assoc 1964;76: 142-147.
36. Pirart J. Diabetes mellitus and its degenerative complications: a prospective study of 4,400 patients observed between 1947 and 1973. Diabetes Care 1978;1: 168-188;252-266.
37. Klein R, Klein BEK, Moss SE, et al. Glycosylated hemoglobin predicts the incidence and progression of diabetic retinopathy. JAMA 1988;260:2864-2871.
38. Klein R, Moss SE, Klein BEK, et al. The Wisconsin epidemiologic study of diabetic retinopathy. XI. The incidence of macular edema. Ophthalmology 1989;96:1501-1510.
39. Moss SE, Klein R, Klein BEK. The incidence of vision loss in a diabetic population. Ophthalmology 1989;95:1340-1348.
40. Doft BH, Kingsley LA, Orchard TJ, et al. The association between long-term diabetic control and early retinopathy. Ophthalmology 1984;91:763-769.
41. McCance DR, Atkinson AB, Hadden DR, et al. Long-term glycaemic control and diabetic retinopathy. Lancet 1989;2:824-828.
42. Weber B, Burger W, Hartmann R, et al. Risk factors for the development of retinopathy in children and adolescents with type I (insulin-dependent) diabetes mellitus. Diabetologia 1986;29:23-29.
43. Groop LC, Teir H, Koskimies S, et al. Risk factors and markers associated with proliferative retinopathy in patients with insulin-dependent diabetes. Diabetes 1986;35:1397-1403.
44. Knowler WC, Bennett PH, Ballintine EJ. Increased incidence of retinopathy in diabetics with elevated blood pressure: a six-year follow-up study in Pima Indians. . Engl J Med 1980;302:645-650.
45. Klein BEK, Moss SE, Klein R. Effect of pregnancy on progression of diabetic retinopathy. Diabetes Care 1990;13:34-40.
46. Leslie RDG, Pyke DA. Diabetic retinopathy in identical twins. Diabetes 1982; 31:19-21.
47. Cohen R, Hennekens CH, Christen CG, et al. Determinants of retinopathy progression in type 1 diabetes mellitus. Am J Med 1999;107:45-51.
48. Moss SE, Klein R, Klein BE. Association of cigarette smoking with diabetic retinopathy. Diabetes Care 1991;14:119-126.
49. Cohen AJ, McGill PD, Rossetti RG, et al. Glomerulopathy in spontaneously diabetic rat: impact of glycemic control. Diabetes 1987;36:944-951.
50. Steffes MW, Buchwald H, Wigness BD, et al. Diabetic nephropathy in the uninephrectomized dog: microscopic lesions after one year. Kidney Int 1982; 21:721-724.
51. Andersen AR, Christiansen JS, Andersen JK, et al. Diabetic nephropathy in type I (insulin-dependent) diabetes: an epidemiological study. Diabetologia 1983;25:496-501.
52. Rosenstock J, Raskin P. Early diabetic nephropathy: assessment and potential therapeutic interventions. Diabetes Care 1986;9:529-545.
53. Kussman MJ, Goldstein HH, Gleason RE. The clinical course of diabetic nephropathy. JAMA 1976;236:1861-1863.
54. Viberti GC, Jarrett RJ, Mahmud U, et al. Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus. Lancet 1982;1: 1430-1432.
55. Parving H-H, Oxenboll B, Svendsen PA, et al. Early detection of patients at risk of developing diabetic nephropathy. A longitudinal study of urinary albumin excretion. Acta Endocrinol 1982;100:550-555.
56. Mathiesen ER, Oxenboll B, Johansen K, et al. Incipient nephropathy in type I (insulin-dependent) diabetes. Diabetologia 1984;26:406-410.
57. Mogensen CE, Christensen CK. Predicting diabetic nephropathy in insulindependent patients. . Engl J Med 1984;311:89-93.
58. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. . Engl J Med 1984;310:356-360.
59. Feldt-Rasmussen B, Mathieson ER. Validity of urinary albumin excretion in incipient diabetic nephropathy. Diabet Nephrol 1984;3:101-104.
60. Chavers BM, Bilous RW, Ellis EN, et al. Glomerular lesions and urinary albumin excretion in type I diabetes without overt proteinuria. . Engl J Med 1989;320:966-970.
61. Perkins BA, Ficociello LH, Silva K, et al. Regression of microalbuminuria in type 1 diabetes. . Engl J Med 2003;348:2285-2293.
62. Krolewski AS, Canessa M, Warram JH, et al. Predisposition to hypertension and susceptibility to renal disease in insulin-dependent diabetes mellitus. . Engl J Med 1988;318:140-145.
63. Rossing P, Hougaard P, Parving HH. Risk factors for development of incipient and overt diabetic nephropathy in type 1 diabetic patients. Diabetes Care 2002;25:859-864.
64. Chaturvedi N, Bandinelli S, Mangili R, et al. Microalbuminuria in type 1 diabetes: rates, risk factors and glycemic thresholds. Kidney Int 2001;60: 219-227.
65. Chase HP, Jackson WE, Hoops SL, et al. Glucose control and the renal and retinal complications of insulin-dependent diabetes. JAMA 1989;261: 1155-1160.
66. Ward JD, Fisher DJ, Barnes CG, et al. Improvement in nerve conduction following treatment in newly diagnosed diabetics. Lancet 1971;1:428-430.
67. The DCCT Research Group. Factors in development of diabetic neuropathy. Baseline analysis of neuropathy in feasibility phase of the Diabetes Control and Complications Trial (DCCT). Diabetes 1988;37:476-481.
68. Porte D Jr, Graf RJ, Halter JB, et al. Diabetic neuropathy and plasma glucose control. Am J Med 1981;70:195-200.
69. Nathan DM. Modern management of insulin-dependent diabetes mellitus. Med Clin North Am 1988;72:1365-1378.
70. The Kroc Collaborative Study Group. Blood glucose control and the evolution of diabetic retinopathy and albuminuria: a preliminary multicenter trial. . Engl J Med 1984;311:365-372.
71. Lauritzen T, Frost-Larsen K, Larsen H-W, et al. The Steno Study Group: twoyear experience with continuous subcutaneous insulin infusion in relation to retinopathy and neuropathy. Diabetes 1985;34[Suppl 3]:74-79.
72. Brinchmann-Hansen O, Dahl-Jorgensen K, Hanssen KF, et al. The response of diabetic retinopathy to 41 months of multiple insulin injections, insulin pumps, and conventional insulin therapy. Arch Ophthalmol 1988;106:1242-1246.
73. Reichard P, Nilsson B-Y, Rosenqvist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. . Engl J Med 1993;329:304-309.
74. The Diabetes Control and Complications Trial (DCCT). Design and methodologic considerations for the feasibility phase. The DCCT Research Group. Diabetes 1986;35:530-545.
75. Lauritzen T, Larsen H-W, Larsen K-F, et al., and the Steno Study Group. Effect of 1 year of near-normal blood glucose levels on retinopathy in insulindependent diabetics. Lancet 1983;1:200-204.
76. Dahl-Jorgensen K, Brinchmann-Hansen O, Hanssen KF, et al. Rapid tightening of blood glucose control leads to transient deterioration of retinopathy in insulin dependent diabetes mellitus: the Oslo study. BMJ 1985;290:811-815.
77. The effect of intensive diabetes treatment on the progression of diabetic retinopathy in insulin-dependent diabetes mellitus: The Diabetes Control and Complications Trial. Arch Ophthalmol 1995;113:36-51.
78. Diabetes Control and Complications Trial Research Group. Progression of retinopathy with intensive vs conventional therapy in the Diabetes Control and Complications Trial. Ophthalmology 1995;102:647-661.
79. The Diabetes Control and Complications Research Group. Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial. Arch Ophthalmol 1998;116:874-886.
80. The Diabetes Control and Complications (DCCT) Research Group. The effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. Kidney Int 1995;47:1703-1720.
81. The Diabetes Control and Complications Research Group. The effect of intensive diabetes therapy on the development and progression of neuropathy. Ann Intern Med 1995;122:561-568.
82. The effect of intensive diabetes therapy on measures of autonomic nervous system function in the Diabetes Control and Complications Trial (DCCT). Diabetologia 1998;41:416-423.
83. The effect of intensive treatment of diabetes on nerve conduction measures in the Diabetes Control and Complications Trial. Ann Neurol 1995;38:869-880.
84. The effect of intensive diabetes therapy on macrovascular disease and its risk factors in the Diabetes Control and Complications Trial. Am J Cardiol 1995; 75:894-903.
85. Influence of intensive therapy on quality-of-life outcomes in the Diabetes Control and Complications Trial. Diabetes Care 1996;19:195-203.
86. Effects of intensive diabetes therapy on neuropsychological function in adults in the Diabetes Complications and Control Trial. Ann Intern Med 1996;124;379-388.
87. The Diabetes Control and Complications Trial Research Group. Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the Diabetes Control and Complications Trial. A randomized, controlled trial. Ann Intern Med 1998;128:517-523.
88. Implementation of treatment protocols in the Diabetes Control and Complications Trial. Diabetes Care 1995;18:361-374.
89. Adverse events and their association with treatment regimens in the Diabetes Control and Complications Trial. Diabetes Care 1995;18:1415-1427.
90. The Diabetes Control and Complications Research Group. Hypoglycemia in the Diabetes Control and Complications Trial. Diabetes 1997; 46:271-286.
91. The Diabetes Control and Complications Research Group. Lifetime benefits of intensive therapy as practiced in the Diabetes Control and Complications Trial. JAMA 1996;276:1409-1415.
92. Pregnancy outcomes in the Diabetes Control and Complications Trial. Am J Obstet Gynecol 1996;174:1343-1353.
93. The relationship of glycemic exposure (HbA1c) to the risk of developing retinopathy in the Diabetes Control and Complications Trial. Diabetes 1995; 44:968-983.
94. The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial. Diabetes 1996;45:1289-1298.
95. Epidemiology of Diabetes Interventions and Complications (EDIC). Design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort. Diabetes Care 1999;22:99-111.
96. The Diabetes Control and Complication Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. . Engl J Med 2000;342:381-389.
97. DCCT/EDIC Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 2002;287:2563-2569.
98. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Intensive diabetes therapy and carotid-intima thickness in type 1 diabetes mellitus. . Engl J Med 2003;348:2294-2303.
99. DCCT/EDIC Research Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy. The Epidemiology of Diabetes Interventions and Complications Study. JAMA 2003;290:2159-2167.
100. Early Treatment Diabetic Retinopathy Study Research Group. Fundus photographic risk factors for progression of diabetic retinopathy. EDTRS Report number 12. Ophthalmology 1991;98[5 Suppl]:823-833.
101. Diabetes Control and Complications Research Group. Clustering of longterm complications in families with diabetes in the Diabetes Control and Complications Trial. Diabetes 1997;46:1829-1839.
102. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. VI. Supplementary report on nonfatal events in patients treated with tolbutamide. Diabetes 1976;25:1129-1153.
103. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995;28:103-117.
104. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive bloodglucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-865.
105. U.K. Prospective Diabetes Study Group. U.K. Prospective Diabetes Study 16. Overview of 6 years' therapy of type II diabetes, a progressive disease. Diabetes 1995;44:1249-1258.
106. Turner RC, Cull CA, Frighi V, et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA 1999;281:2005-2112.
107. Nathan DM. Some answers, more controversy, from UKPDS. Lancet 1998;352:832-833.
108. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham Study. JAMA 1979;241:2036-2038.
109. Gordon T, Castelli WP, Hjortland MC, et al. Diabetes, blood lipids, and the role of obesity in coronary heart disease risk for women. The Framingham Study. Ann Intern Med 1977;87:393-397.
110. Jarrett RJ, McCartney P, Keen H. The Bedford Survey: ten-year mortality rates in newly diagnosed diabetics, borderline diabetics and normoglycemic controls and risk indices for coronary heart disease in borderline diabetics. Diabetologia 1982;22:79-84.
111. Wingard DL, Barrett-Connor E, Criqui MH, et al. Clustering of heart disease risk factors in diabetic compared to nondiabetic adults. Am J Epidemiol 1983;117:19-26.
112. The International Collaborative Group. Joint discussion. . Chronic Dis 1979;32:829-837.
113. Singer DE, Nathan DM, Anderson KM, et al. The association of hemoglobin A1c with prevalent cardiovascular disease in the original cohort of the Framingham Heart Study. Diabetes 1992:41:202-208.
114. Stratton IM, Adler AI, Neil HAW, et al. Association of glycemia with macrovascular and microvascular complication of type 2 diabetes (UKPDS 35) Prospective Observational Study. BMJ 2000;321:405-419.
115. The Diabetes Prevention Program. Design and methods for a clinical trial in the prevention of type 2 diabetes mellitus. Diabetes Care 1999;22:623-634.